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ABSTRACT  
Background and Aims 
Direct-acting antivirals (DAAs) are highly effective in treating hepatitis C. However, there is 
concern that cure rates may be lower, and reinfection rates higher, amongst people who inject 




A search strategy was used to identify studies that reported sustained viral response (SVR), 
treatment discontinuation, adherence or reinfection in recent PWID and/or opioid substitution 
therapy (OST) recipients. Study quality was assessed using the Newcastle-Ottawa Scale. 
Meta-analysis of proportions was used to estimate pooled SVR and treatment discontinuation 
rates. The pooled relative risk of achieving SVR was also calculated using a generalised 
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Results 
The search identified 8075 references; 26 were eligible for inclusion. The pooled SVR for 
recent PWID was 88% (95% CI, 83% – 92%) and 91% (95% CI 88% – 95%) for OST 
recipients. The relative risk of achieving SVR for recent PWID compared to non-recent 
PWID was 0.99 (95% CI, 0.94 – 1.06). The pooled treatment discontinuation was 2% (95% 
CI, 1% – 4%) for both recent PWID and OST recipients. Amongst recent PWID the pooled 
incidence of reinfection was 1.94 per 100 person years (95% CI, 0.87 – 4.32). In OST 
recipients, the incidence of reinfection was 0.55 per 100 person years (95% CI, 0.17 – 1.76).   
 
Conclusions 
Treatment outcomes were similar in recent PWID compared to non-PWID treated with 
direct-acting antivirals. People that report recent injecting or OST recipients should not be 













• People who inject drugs are currently excluded from hepatitis C 
treatment by jurisdictions and individual practitioners, partially 
based on concerns regarding efficacy and reinfection risk 
 
• We identified 26 studies which reported treatment outcomes or 
people who inject drugs and/or people receiving opioid substitution 
therapy, including cure and reinfection.  
 
• People who inject drugs, as well as OST recipients, both achieved 
high rates of hepatitis C cure  
 
• The risk of reinfection after treatment was relatively low, however 
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BACKGROUND 
 
Hepatitis C (HCV) is a blood-borne virus, which in high-income countries is primarily 
transmitted amongst people who inject drugs (PWID).1,2 Curing HCV reduces mortality and 
improves quality of life.3,4 Treating PWID also reduces the risk of transmission, and is an 
essential component of achieving the World Health Organization HCV elimination targets.5 
Despite recommendations that PWID receive treatment,6-8 this population continues to be 
excluded; both by individual practitioners,9 and at a systemic level.10,11  
 
Our 2013 systematic review of interferon/ribavirin therapy found that PWID receiving 
treatment had high levels of adherence (82%, 95% CI 74% - 89%), low treatment 
discontinuation (22%, 95% CI 16% - 27%), and similar SVR rates (56%, 95% CI 50% - 
61%) to non-PWID in real-world settings.12 A systematic review of treatment outcomes in 
people reporting recent drug use, including a subgroup of people who inject drugs, found that 
this population achieves relatively high rates of cure with DAAs.13 Despite the effectiveness 
of DAAs, concerns about reinfection in PWID have been raised and may partially account for 
practitioner unwillingness to prescribe DAA therapy to this population.9   
 
Low rates of reinfection were observed among those PWID treated with interferon-based 
therapies,12,14 but this may be different in the DAA era. Indeed, given that DAA treatments 
are significantly more effective and tolerable than interferon-based therapies, it is possible 
that the availability of DAA treatment may result in an increase in the number of people with 
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Several studies have investigated DAA therapy outcomes amongst PWID, including 
reinfection, but the number of recent PWID included in each study is small (range: 23 – 
163).15-27 We conducted a systematic review and meta-analysis to measure SVR, treatment 
discontinuation, adherence, and reinfection amongst recent PWID and OST recipients treated 




Study identification  
In November 2017, a search strategy (see Supplementary Material) was used to identify 
relevant English-language studies in MEDLINE, Embase, Cochrane Central Register of 
Controlled Trials (CENTRAL), and Web of Science. Search results were limited to the year 
2010 and onward. Proceedings from The International Liver Congress (EASL), The Liver 
Meeting (AASLD), and the International Symposium on Hepatitis Care in Substance Users 
(INHSU) from 2015 to 2017 were also searched. The review protocol was prospectively 
registered with PROSPERO (CRD42017083604). 
 
Study selection  
Search results were uploaded to Covidence (Melbourne, AU) and independently assessed by 
two reviewers using pre-specified criteria (Table 1). Authors of studies that included, but did 
not report outcomes for, recent PWID were contacted for additional data. Studies that 
reported SVR, reinfection, treatment discontinuation and/or adherence in recent PWID and/or 
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Data extraction  
Data were extracted independently by two reviewers using a standardized spreadsheet. Where 
a study resulted in multiple publications, the most up-to-date data available was used. The 
following data were extracted:   
 
Study and participant characteristics  
Country, setting, study design, number of study sites, treatment regimen, adherence 
intervention, inclusion and exclusion criteria, definition(s) of recent PWID, number of OST 
recipients, previous substance use, age, gender, genotype and cirrhosis were extracted.  
 
Primary outcome 
The primary outcome was SVR, defined as undetectable HCV RNA at least 12 weeks after 
treatment completion. SVR was extracted on an intention-to-treat, modified intention-to-treat 
(participants that were missing SVR test results, but had attained undetectable HCV RNA at 
end of treatment were assumed to be cured) and/or according to study definitions.  
 
Secondary outcomes 
The definition of adherence and the number of participants meeting this definition were 
extracted. Treatment discontinuation was defined as the number of participants that 
commenced, but did not complete therapy, including those that died during treatment. 
Reinfection was defined as detectable HCV RNA after SVR, or after treatment completion in 
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Risk of bias  
The Newcastle-Ottawa Scale (NOS),28 was used to assess the quality of included studies. 
Each study was independently scored from zero (low quality) to nine (high quality) by two 
reviewers. Studies without a comparison group were assessed using a modified scale (score 
out of six). Sensitivity analyses were conducted excluding studies scoring ≤6 (out of 9) or ≤4 
(out of 6) on the relevant scale. A funnel plot was used to assess publication bias.  
 
Data synthesis and analysis 
All statistical analyses were performed using Stata 15 (StataCorp, College Station, USA). 
 
Random-effects meta-analysis of proportions was used to estimate the pooled SVR in recent 
PWID and OST recipients using the Stata metaprop_one package.29 Standard errors were 
calculated using the Wilson method. The Freeman-Tukey arcsine transformation was used for 
studies where all patients achieved SVR. 
 
Pooled relative risks of achieving SVR in recent PWID and OST recipients (compared to 
non-recent PWID or non-OST recipients, respectively) were calculated using DerSimonian 
and Laird random-effects models (for I2=25-75%) or Mantel and Haenszel fixed-effects 
models (for I2<25%) using the Stata metan package.30,31  
 
SVR was calculated on an intention-to-treat (ITT) and modified intention-to-treat 
(mITT)/other basis. To be included in the ITT analysis, a study was required to report the 
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SVR in recent PWID and OST recipients  
The relative risk of achieving SVR in recent PWID and OST recipients (compared to non-
recent PWID or non-OST recipients, respectively) was calculated. In studies where all 
participants met the primary definition of recent PWID, the secondary definition was used in 
the relative risk calculation. A constant continuity correction (0.5) was used for meta-analysis 
of relative risk.32 
 
Post-treatment reinfection in recent PWID and OST recipients 
The pooled reinfection rate was calculated using a generalised mixed-effects linear model 
with a poisson family, log link function and a random effect for study.   
 
Secondary outcomes  
Meta-analysis of proportions was used to estimate the pooled proportion discontinuing 
treatment in recent PWID and OST recipients.  
 
Studies where all patients achieved SVR 
In studies where all patients achieved SVR, the Freeman-Tukey double arcsine 
transformation was used for meta-analysis of proportions and a constant continuity correction 
(0.5) was used for meta-analysis of relative risk.32  
 
Additional analyses  
Pre-specified subgroup and sensitivity analyses were performed examining the effect of 
country (high- vs. middle- income), setting (real-world vs. clinical trial), recent PWID 
definition, adherence intervention (any vs. none), and study quality (all studies vs. high-
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transformations or continuity corrections, and with an alternative continuity correction (the 
reciprocal of the opposite group arm size).33 
 
RESULTS  
The search yielded 8075 studies, of which 155 were eligible for full-text review (Figure 1). 
Of the 26 included studies, 14 reported outcomes for recent PWID and 19 reported outcomes 
for OST recipients.  
 
Study characteristics  
 
Studies reporting SVR 
Thirteen studies reported SVR in recent PWID, of which the majority (n=10) were real-world 
studies conducted in high-income countries. Recent PWID were most commonly defined as 
people reporting injecting in the past 6 months (n=5). Other definitions were injecting: during 
treatment (n=2); in the past year (n=2); the past month (n=2). The remaining two studies 
defined recent PWID as people attending a needle syringe program at the time of recruitment 
(n=1), or in the past year (n=1). Seven studies provided adherence support services. Two 
offered directly observed therapy (DOT); one of which required all participants to receive 
daily DOT.  
 
Nineteen studies reported SVR in OST recipients. The characteristics of these studies are 
summarised in Table 2. The vast majority (n=18) were conducted in high-income countries; 
eight of which were clinical trials. Seven studies, provided adherence support; including daily 
DOT for all participants (n=3), dispensing medication at a needle syringe program (n=1), and 
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Studies reporting adherence and discontinuation  
Six studies (Table 4) reported adherence, five of which were clinical trials. Most (n=5) 
reported adherence in OST recipients; only two reported adherence for recent PWID.27,34 
Adherence was most commonly defined as the percentage of doses taken and ranged from 
≥80% (n=1),35 ≥90% (n=3),34,36,37 and >95% (n=1).38 The remaining study provided 
participants with daily DOT, and noted that no participants missed more than one dose.27 In 
studies that did not provide adherence support, adherence was assessed by pill count (n=3),35-
37 a participant-completed electronic medication diary (n=1),38 or an electronic blister back 
(n=1).34 Fifteen studies reported treatment discontinuation: in recent PWID (n=5),17,19,22,27,34 
or OST recipients (n=10).22,27,35-37,39-43 Reasons for discontinuation included death, 
incarceration, and loss to follow-up.  
 
Studies reporting reinfection 
Nine studies (Table 3) reported reinfection data; six for recent PWID and four for OST 
recipients. The follow-up period during which reinfection could be detected ranged from 24 
weeks to three years after treatment completion. Early reinfection was distinguished from 
treatment failure by comparison of genotype/subtype and/or viral sequencing.  
 
Risk of bias  
The mode NOS score was seven out of nine (range 5 – 9) for studies that included a 
comparison group (n=14). Amongst studies without comparison groups (n=12) the mode 
NOS score was five out of six (range 4 – 6). In total 16 studies, were deemed to be of high 
quality (NOS ≥7 or modified NOS ≥5). In studies with comparison groups, the most common 
source of potential bias was a possible difference between the recent PWID or OST group 
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genotype.15,20,22,24-27,36,37,40,44-46 This was either due to lack of reporting of baseline 
characteristics by recent PWID or OST group, or reporting of a statistically significant 
difference between groups. Ten studies were also deemed to be at high risk of bias in terms 
of the representativeness of the recent PWID or OST group.27,35-38,40-42,47,48 The most common 
(n=6) potential source of bias in this domain was the requirement that participants be on 
‘stable OST’.27,35,37,38,41,42 Seven of the nine studies that reported reinfection followed 
participants for less than one year after treatment completion and were thus deemed to be at 
high risk of bias for this outcome. There was no evidence of publication bias for the relative 
risk of SVR in recent PWID and OST recipients (Supplementary Figure).  
 
Synthesis of results  
 
Pooled SVR in recent PWID  
SVR data was presented for recent PWID across 13 studies. Amongst the ITT population 
(n=827) the pooled SVR was 88% (95% CI 83% – 92%; Figure 2a). There was substantial 
heterogeneity (I2 = 74%), which persisted when the analysis was limited to real-world studies 
conducted in high-income countries (I2 = 68%). In the mITT/as-defined analysis, 10 studies 
of 665 recent PWID were included. The pooled SVR in recent PWID was 91% (95% CI: 
86% – 95%; Figure 2b) with considerable heterogeneity (I2=75%).  
 
Pooled SVR in OST recipients   
Nineteen studies presented SVR data for OST recipients. In the ITT population (n=1086) the 
pooled SVR was 91% (95% CI 87% – 95%; Figure 2c). There was substantial heterogeneity 
(I2=72%), which persisted when the analysis was limited to real-world studies in high-income 
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can be largely attributed to one study,27 which had a markedly different methodology 
(intensive case management) and yielded an SVR of 100%. Limiting the analysis to clinical 
trials yielded a pooled SVR of 94% (95% CI, 92% – 96%) with minimal heterogeneity 
(I2=15%). In the mITT/as-defined analysis (Figure 2d) the pooled SVR was 98% (95% CI, 
94% - 100%) with substantial heterogeneity (I2=63%).  
 
Relative risk of achieving SVR in recent PWID 
Compared to people not reporting recent injecting, the pooled relative risk of achieving SVR 
in recent PWID was 0.99 (95% CI, 0.93 – 1.05, p=0.67; Figure 3a) in the ITT population and 
0.94 (95% CI, 0.89 – 0.99, p=0.01) in the mITT/as-defined population. Moderate 
heterogeneity (I2=36%) was observed in the ITT analysis but not the mITT/as-defined 
analysis (I2=15%).  
 
Relative risk of achieving SVR in OST recipients  
Compared to non-OST recipients, the pooled relative risk of achieving SVR in OST 
recipients was 0.97 (95% CI, 0.95 – 0.997, p=0.03; Figure 3b) in the ITT population and 1.00 
(95% CI, 0.97 – 1.03, p=0.98) in the mITT/as-defined population. No heterogeneity was 
observed in these analyses (I2=0%).  
 
Treatment discontinuation  
Five studies (Supplementary Table) reported treatment discontinuation in recent PWID. 
Amongst recent PWID (n=342) the pooled discontinuation was 2% (95% CI, 1% – 4%). No 
heterogeneity was observed (I2=0%). The pooled estimate was identical for the nine studies 
that reported discontinuation in OST recipients (n=570). There were insufficient studies with 
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Adherence  
There were insufficient primary data (n=2) on adherence to derive pooled estimates for recent 
PWID. Adherence is summarised in Table 4. 
 
Reinfection  
Amongst people reporting recent injecting, the pooled incidence of reinfection was 1.94 per 
100 person years (95% CI, 0.87 – 4.32). In OST recipients, the incidence of reinfection was 
0.55 per 100 person years (95% CI, 0.17 – 1.76).  
 
Sensitivity analyses  
None of the results were sensitive to exclusion of low quality studies, exclusion of studies 
that did not define recent PWID as injection within a specified timeframe prior to treatment 
initiation, use or modification of the continuity correction, or use of the Freeman-Tuckey 
arcsine transformation.  
 
DISCUSSION 
Recent PWID and OST recipients achieve high rates of SVR when treated with DAAs (88% 
and 91%, respectively). The SVR rate was at least 75% for recent PWID in all but one small 
study conducted in a lower-middle-income country (n=25; SVR=64%).22 Importantly, when 
recent PWID were compared to people not reporting recent injecting, there was no clinically 
significant difference in SVR attainment (RR 0.99; 95% CI, 0.93 – 1.05). This was also true 
for people receiving OST during treatment (RR 0.97; 95% CI, 0.95 - 1). Our review 
highlights that routinely excluding recent PWID from treatment is not supported by evidence 
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Treatment discontinuation was very low amongst recent PWID and OST recipients 
(approximately 2% in both groups) highlighting the high tolerability of DAA regimens and 
the capacity of recent PWID and OST recipients to complete treatment. Of the few studies 
that reported various definitions of adherence, the number of participants deemed to be 
adherent was almost always greater than 90%. In the one study of recent PWID in which 
adherence was relatively low (66%) the vast majority of participants (94%) still achieved 
SVR.34 This is consistent with other real-world studies that did not meet the inclusion criteria 
for this review but reported adherence in cohorts with large proportions of recent PWID or 
OST recipients. A study of 61 patients (95% OST recipients) found that 41% took at least 
80% of doses on the correct day (measured by an electronic blister pack).49 A study of 23 
participants receiving directly observed therapy (93% recent PWID, 85% OST recipients) 
found that 48% received >90% of doses on the correct day.50 In both studies, missed doses 
were made up at a later date, and preliminary SVR results were high. A third study conducted 
in alcohol and other drug clinics (50% recent PWID, 38% OST recipients) reported 93% 
adherence but this was measured by self-report.24 More primary data is required to 
characterise the relationship between adherence and SVR in recent PWID and OST 
recipients, but the available evidence suggests that even in the context of low adherence, high 
SVR rates are achievable. 
 
Our review found low pooled rates of HCV reinfection. While this is encouraging, it is 
important to note that the observation period for reinfection in most of the included primary 
studies was relatively short. At the very least, our results suggest that the vast majority of 
recent PWID remain free from reinfection for at least 24 weeks following the end of 
treatment. The length of follow up after HCV treatment in primary studies of recent PWID is 










This article is protected by copyright. All rights reserved. 
follow-up periods for established studies. In the interim, it is encouraging that low rates of 
reinfection were observed in the small number of currently available studies with longer 
follow-up periods.18,51,52  
 
Even if subsequent studies with longer follow-up periods and a greater number and diversity 
of PWID and OST recipients demonstrate lower rates of SVR or a higher rate of reinfection, 
it is essential that these groups not be excluded from treatment. Indeed, that an individual 
who achieves an EoTR or SVR subsequently becomes reinfected highlights that the initial 
treatment reached an individual at high risk of not only acquiring, but also transmitting, 
hepatitis C – a population that is essential to treat to achieve the WHO elimination goals.5 To 
this end, instead of attempting to reduce reinfection by precluding those with risk factors 
from treatment, reinfection should be proactively prevented: through education to treatment 
recipients with risk factors and providing consistent access to harm reduction services 
including syringe services and medication assisted treatment during and after treatment. After 
completing treatment, individuals at risk for reinfection should remain under surveillance for 
reinfection and be promptly re-treated.  
 
A key strength of our review is that it is the first of which we are aware to quantitatively 
synthesise data for reinfection after treatment with DAAs for recent PWID and OST 
recipients. In addition by systematically contacting authors where necessary to obtain 
outcome data by injecting behaviour, our review expands the currently available body of 
evidence and is the largest review of SVR in recent PWID (n=827 in the ITT analysis).  
Synthesising the results of these studies is particularly important given that the majority of 











This article is protected by copyright. All rights reserved. 
Despite these strengths, our review also had a number of limitations. Classification of recent 
PWID varied between studies so the categorisation used in this review included a broad 
spectrum of injecting behaviour: from injecting during treatment to injecting in the 12 months 
prior to treatment. The analysis of reinfection risk is also limited by the length of the follow 
up periods in the primary studies. It is also possible that the selection processes of the 
individual studies favoured people that were already relatively well engaged in healthcare 
and who may have relatively better treatment outcomes, including lower rates of reinfection. 
The extent to which this occurred is not apparent as most studies did not report indicators of 
social stability including housing and employment. While most studies did report other 
baseline characteristics such as genotype and cirrhosis, very few studies reported these 
characteristics by the sub-groups of interest (recent PWID, OST recipients). As such, it was 
not possible to perform a meta-regression of SVR for either of the populations included in 
our review. 
 
Our review highlights that recent PWID treated with DAAs consistently complete treatment, 
obtain high rates of SVR and largely avoid early reinfection. There was no clinically 
significant difference between recent PWID and OST recipients compared to other patients. 
These findings are particularly important because despite recommendations from EASL and 
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Population Recent PWID, primarily defined as people who reported injecting 
drugs within the year prior to treatment for chronic hepatitis C  
and/or 
People receiving opioid substitution therapy (OST) at the time of  
treatment for chronic hepatitis C 
 
Studies where the above group(s) only comprised a proportion of 
all study participants were eligible provided: that there were at 
least 15 participants in either of the above group(s); and that the 
outcome(s) of interest were reported for this/these group(s)  
 
Participants treated in a custodial setting were excluded  
Intervention Treatment with any interferon-free direct-acting antiviral 
regimen.  
 
Studies which included a combination of interferon-free and 
interferon-containing regimens were eligible provided that 
population and outcome data were reported in the study for the 
interferon-free group (or if this information was made available 
by the authors) 
Comparison  No comparison group 
or 
The same intervention in non-recent PWID or people not 
receiving OST 
Outcome  SVR (undetectable hepatitis C RNA at least 12 weeks after 
treatment completion) 
and/or 
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*Additional data or information not included in the primary citation provided by author 
† This paper also included participants treated with SOF/VEL, however outcomes for this treatment group were 
already extracted in Grebely 2016a 
‡ People reporting ‘clinically significant’ substance use in the past year and/or those with a positive urine drug 
screen (for non-cannabinoids) were excluded from these trials 
# Paper reports reinfection only  
 
Abbreviations: DAA, direct-acting antiviral; DCV, daclatasvir; EBR, elbasvir; GLE, glecaprevir; GZR, 
grazoprevir; ITT, intention-to-treat; LDV, ledipasvir; mITT, modified intention-to-treat; NR, not reported; OC, 
observational cohort; OST, opioid substitution therapy; PC, prospective cohort; PrO, 
paritaprevir/ritonavir/ombitasvir; PrOD, paritaprevir/ritonavir/ombitasvir plus dasabuvir; PWID, people who 
inject drugs; RBV, ribavirin; RC, retrospective cohort; RCT, randomised controlled trial; SOF, sofosbuvir; 
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2017 17,52 † 
Recurrence after 
SVR12 through 








[0.1 - 4.4] 
- - - 
Conway  
2016 18 
Recurrence 3 – 
12 months after 
SVR12 
0 (0/32) 32 
0.0  
[0.0 - 0.1] 
- - - 
Conway  











through to up to 
36 months of 
follow up  
(viral 
sequencing)  
- - - 




















- - - 0 (0/66) 1822 
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1.0 (1/97) 38 
2.6  
[0.1 - 14.7] 










2.4 (2/83) 71 
2.8  
[0.3 - 10.2] 









4.3 (1/23) 5.3 
18.9  
[0.5 -105.1] 
5 (2/40) 9 
22.2  
[2.7-80.3] 
# Exact 95% Poisson confidence interval 
† Reinfection data from a subsequent publication and/or author contact 
*This study had two follow up periods; 169 participants were followed for 9 months after EoTR, of whom 156 were 
followed for an additional period. 
** This study had two follow up periods, 296 participants received 24 weeks of follow up. Of these, 199 were followed for 
an additional period  
 Abbreviations: EoTR, end of treatment response; NR, not reported; OST, opioid substitution therapy; PWID, people who 
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Grebely 2016 35 None 
≥80% of doses 
taken 
Pill count at 
weeks 4, 8, ±12 
- 93 (65/70) 
92 
(1737/1882) 
Grebely 2016a 37 None 
≥90% of doses 
taken 
Pill count at all 
study visits 
- 90 (46/51) 
96 
(946/984) 
Grebely 2017 36 None 














≥90% of doses 
taken 
Electronic 
blister back that 
recorded time 
and date that 
each dose was 
accessed 
66 (68/103) - - 
 
Abbreviations: OST, opioid substitution therapy; PWID, people who inject drugs  
*All recent PWID were on OST  
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                                         Figure 2:(a) SVR in recent PWID (ITT) 
ITT, intention-to-treat analysis; mITT, modified intention-to-treat analysis; OST, opioid substitution therapy; 
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                                    Figure 2:(b) SVR in recent PWID (mITT/as-defined) 
ITT, intention-to-treat analysis; mITT, modified intention-to-treat analysis; OST, opioid substitution therapy; 
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                                             Figure 2:(c) SVR in OST recipients (ITT) 
ITT, intention-to-treat analysis; mITT, modified intention-to-treat analysis; OST, opioid substitution therapy; 
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                             Figure 2:(d) SVR in OST recipients (mITT/as-defined) 
ITT, intention-to-treat analysis; mITT, modified intention-to-treat analysis; OST, opioid substitution therapy; 
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Figure 3:(a) Relative risk of achieving SVR in recent PWID 
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Figure 3:(b) Relative risk of achieving SVR in OST recipients 
 
OST, opioid substitution therapy; SVR, sustained viral response 
